ABBV-466 Phase 2a Signal Is Real But Pre-Pivotal: Dual Mechanism Outperforms Components, Proof Remains Incomplete

AbbVie's ABBV-466 Shows Superior Endoscopic Remission in Crohn's Disease

AbbVie announced positive Phase 2a data for its investigational dual-targeting therapy, ABBV-466, in patients with moderate to severe Crohn's disease (CD). The TARGET-CD study showed ABBV-466 achieved higher endoscopic remission rates than either anti-IL-23 p19 (risankizumab) or anti-α4β7 (trosunilimab) monotherapy. At Week 12, 30.2% of ABBV-466 patients achieved endoscopic remission, compared to 21.3% and 18.0% for monotherapies, respectively. This difference further increased by Week 24, with 40.5% of ABBV-466 patients achieving remission versus 22.4% and 20.0% for monotherapies. These findings will be presented at the 2026 Annual United European Gastroenterology Week Congress.

• ABBV-466 demonstrated superior efficacy at Week 12, the primary endpoint, achieving endoscopic remission in 30.2% of patients with moderate to severe Crohn's disease. This significantly surpassed the rates observed with risankizumab monotherapy (21.3%) and trosunilimab monotherapy (18.0%), highlighting the immediate benefit of the dual-targeting approach in a complex patient population.
• The therapeutic advantage of ABBV-466 was further amplified at Week 24, with 40.5% of treated patients achieving endoscopic remission. This sustained and growing improvement over time, compared to 22.4% for risankizumab and 20.0% for trosunilimab, suggests a more profound and durable disease control with the combination therapy.
• Molecular analyses revealed that ABBV-466 induced colonic epithelial repair and barrier restoration by Week 12, followed by tissue remodeling and metabolic changes at Week 24, effects largely absent in monotherapy groups. Furthermore, the safety profile of ABBV-466 was comparable to monotherapies, with serious adverse events reported at 10.4% for ABBV-466, 9.6% for risankizumab, and 9.0% for trosunilimab.

Unpacking AbbVie's Dual-Targeting Strategy for Crohn's Disease

Several novel therapeutic targets are under active investigation for Crohn's disease. The JAK/STAT signaling pathway has emerged as a particularly productive area, with JAK inhibitors demonstrating divergent efficacy profiles across compounds. Tofacitinib has shown limited efficacy in Crohn's disease management, while filgotinib, despite initial clinical remission signals in phase 2 trials, failed to demonstrate consistent endoscopic improvement in subsequent phase 3 studies. Upadacitinib has achieved notable clinical remission rates during both induction and maintenance phases of phase 2 trials, positioning it as the most promising JAK inhibitor in Crohn's disease to date. Long-term safety considerations — including thromboembolic events, cardiovascular events, opportunistic infections, and potential malignancy risks — warrant cautious clinical application across this class.

Beyond JAK inhibition, sphingosine-1-phosphate (S1P) receptor modulation represents a mechanistically distinct oral small-molecule approach. S1P receptor modulators act by sequestering lymphocytes within lymphoid organs through functional antagonism of S1P1 receptors, thereby reducing lymphocyte egress from lymph nodes into the systemic circulation and attenuating intestinal inflammation. Ozanimod and etrasimod are the principal agents in this class, with established efficacy in ulcerative colitis and ongoing evaluation in Crohn's disease. Separately, TL1A antagonists have demonstrated early efficacy signals in Crohn's disease, with a pooled clinical response rate of 58% of patients and an odds ratio of 2.96 (95% CI 1.36–6.42) versus placebo, alongside a clinical remission odds ratio of 3.75 (95% CI 2.04–6.89) across both UC and CD populations.

IL-23 p19 inhibitors — including guselkumab, mirikizumab, and risankizumab — represent another emerging class with demonstrated efficacy in both biologic-naïve and biologic-experienced Crohn's disease patients, with clinical and endoscopic superiority over ustekinumab and an excellent safety profile. Selective TYK2 inhibition is also attracting interest; BMS-986202, a selective TYK2 inhibitor, has been shown to spare IL-2 signaling and Treg induction — unlike broader JAK inhibitors such as upadacitinib — while redirecting CD4 T cells toward a regulatory phenotype in lamina propria mononuclear cells from IBD patients under Th17-polarizing conditions, suggesting a potential role in tolerance induction. Gut-selective JAK inhibition, exemplified by lorpucitinib, is an additional strategy under phase 1 evaluation, with tissue concentrations in gut mucosal biopsies 392- to 1928-fold higher than corresponding plasma samples, offering the prospect of local anti-inflammatory activity with reduced systemic exposure.

ABBV-466 Delivers Higher Endoscopic Remission in TARGET-CD

Several recent clinical studies have advanced the understanding of novel therapies for moderately to severely active Crohn's disease, spanning IL-23 inhibitors, JAK1 inhibitors, and combination approaches. The findings below reflect key efficacy and safety data from phase 2, phase 3, and real-world investigations.

• GALAXI-1 (Guselkumab): This phase 2, randomised, double-blind trial evaluated intravenous guselkumab induction transitioning to subcutaneous maintenance through week 48. At week 48, CDAI clinical remission was achieved in 64% of patients in the guselkumab 200→100 mg group, 73% in the 600→200 mg group, and 57% in the 1200→200 mg group, compared with 59% in the ustekinumab group. Endoscopic remission (SES-CD ≤2) was observed in 18%, 17%, and 33% of patients across the three guselkumab groups, respectively, versus 6% with ustekinumab. Adverse events occurred in 74% of patients across the three guselkumab groups combined (353.1 events per 100 patient-years), with nasopharyngitis and upper respiratory infections as the most frequently reported infections. No active tuberculosis, opportunistic infections, or deaths occurred through week 48.

• VIVID-1 (Mirikizumab): This phase 3, randomised, double-blind, placebo-controlled and active-controlled treat-through study enrolled adults with moderately to severely active Crohn's disease who had prior inadequate response, loss of response, or intolerance to one or more approved biological or conventional therapies. Both co-primary composite endpoints were met: endoscopic response-composite was reached in 38.0% of patients on mirikizumab versus 9.0% on placebo (p<0.0001), and CDAI clinical remission-composite was reached in 45.4% on mirikizumab versus 19.6% on placebo (p<0.0001). Serious adverse events were reported in 10.3% of mirikizumab-treated patients versus 17.1% on placebo. The most common adverse event across all groups was COVID-19, and none of the three deaths that occurred during the study were considered related to study drug.

• Risankizumab — Systematic Review and Meta-Analysis: A systematic review and meta-analysis incorporating five RCTs and nine observational studies (n=3,275) evaluated risankizumab, a selective IL-23 p19 inhibitor, in moderate-to-severe CD. In RCTs, risankizumab significantly increased clinical remission at induction (RR: 1.90, 95% CI [1.63; 2.20]) and maintenance (RR: 1.34, 95% CI [1.15; 1.55]) versus placebo. Endoscopic remission was also significantly higher at induction (RR: 3.25, 95% CI [2.43; 4.35]) and maintenance (RR: 2.04, 95% CI [1.22; 3.42]). Pooled real-world evidence demonstrated clinical remission rates of 57% at 12 weeks and 44% at 1 year, including in patients with prior ustekinumab failure. No increased risk of serious adverse events was observed.

• VICTRIVA (Vedolizumab + Upadacitinib — Design and Rationale): This phase 3b, randomised, double-blind trial is evaluating whether vedolizumab (300 mg at weeks 0, 2, 6, and 10) combined with upadacitinib 45 mg daily improves rates of clinical remission and endoscopic response at week 12 versus vedolizumab alone in biologic-experienced and biologic-naïve adults with CD. Co-primary endpoints are CDAI clinical remission and SES-CD endoscopic response at week 12; key secondary endpoints include PRO2 clinical remission at week 12 and CDAI clinical remission, SES-CD endoscopic response, and PRO2 clinical remission at week 52. A total of 396 patients (198 per group) will be enrolled globally, with a minimum of 50% and maximum of 50% biologic-naïve. Safety endpoints include the incidence of treatment-emergent adverse events.

Addressing Persistent Inflammation in Heavily Pretreated Crohn's Disease

Despite meaningful advances in biologic and small-molecule therapies, substantial gaps remain in achieving durable disease control across the full spectrum of Crohn's disease (CD) presentations. The literature highlights several distinct populations and clinical scenarios where current therapeutic strategies fall short of optimal outcomes.

• Heavily pretreated / advanced therapy-experienced patients: Real-world data from the UPGRADE-CD study enrolled AT-experienced CD patients initiating upadacitinib, with 48% having failed more than two advanced therapies. Steroid-free clinical remission reached only 51.2% at Week 12 and 54.7% at Week 24, underscoring the limited efficacy ceiling in this refractory population. Similarly, a GETAID cohort of highly refractory CD patients — all previously exposed to at least one biologic (median 4) — achieved steroid-free clinical remission in only 54% at Week 12 with upadacitinib induction.

• Perianal and fistulizing Crohn's disease: Fistulizing CD occurs in up to 30% of patients and long-term fistula healing is achieved in only 30–50% of patients with anti-TNF therapy. Perianal fistulizing disease is associated with significant reductions in quality of life and elevated risk of distal rectal and anal cancers. Non-healing perineal wounds remain a common and morbid complication after intersphincteric proctectomy, with reported healing rates of approximately 70% at 1 year. Emerging approaches — including mesenchymal stem cell therapy, biomaterial-based plugs and fillers, and vacuum-assisted closure — are under investigation but long-term closure remains challenging.

• Deep small intestinal lesions: Evidence regarding therapeutic effectiveness for deep small intestinal involvement in CD remains scarce, as these lesions are often underdiagnosed due to limited accessibility and subtle clinical presentation. A retrospective study using double-balloon endoscopy to evaluate risankizumab found that endoscopic remission (mSES-CD < 2) was achieved in only 13.3% of patients with moderate-to-severe CD affecting the jejunum and deep ileum.

• Patients with transmural and progressive disease not captured by mucosal endpoints: Achieving full transmural healing is uncommon with available therapies. In a prospective study of CD patients with endoscopic healing, 27% lacked intestinal ultrasound transmural healing and faced a cumulative relapse risk of 48% versus 17% in those with transmural healing. Intestinal barrier healing has further been shown to outcompete transmural healing in predicting major adverse outcomes — including disease flares, IBD-related hospitalization or surgery, and initiation or escalation of systemic therapy — highlighting that current treatment targets do not fully capture disease trajectory.

• Post-operative recurrence following ileocolic resection: Postoperative recurrence after ileocaecal resection remains a significant challenge, with one- and three-year clinical recurrence rates of 23.3% and 36.3%, respectively, and endoscopic recurrence rates of 30.1% and 42.8% in a retrospective cohort. Active smoking independently increased endoscopic recurrence risk (HR 2.96; 95% CI 1.18–7.38; p < 0.001), and very few modifiable surgical or medical factors beyond smoking cessation and endoscopy-driven surveillance have demonstrated robust recurrence reduction.

• Newly diagnosed patients at risk of rapid disease progression: The PROFILE trial demonstrated that top-down treatment with combination infliximab plus immunomodulator achieved sustained steroid-free and surgery-free remission in 79% of patients versus only 15% in the accelerated step-up group (absolute difference 64 percentage points; p < 0.0001), with fewer serious adverse events and abdominal surgeries. This positions early aggressive intervention as a critical unmet strategic need, particularly given that a putative T-cell transcriptional biomarker (PredictSURE-IBD) failed to show clinical utility in guiding treatment selection.

ABBV-466: A New Frontier in Crohn's Disease Management

The recent announcement of positive Phase 2a data for AbbVie's investigational dual-targeting therapy, ABBV-466, in moderate to severe Crohn's disease marks a potentially pivotal moment in the management of this chronic inflammatory condition. By simultaneously targeting the IL-23 p19 subunit and the α4β7 integrin, ABBV-466 aims to address two critical pathways implicated in Crohn's disease pathogenesis: the inflammatory cytokine cascade and the gut-specific trafficking of immune cells. Existing evidence highlights the central role of IL-23 in driving inflammation and the importance of α4β7 integrin in mediating lymphocyte infiltration into the intestinal tract.

While therapies like risankizumab (an IL-23 p19 inhibitor) and vedolizumab (an α4β7 integrin inhibitor) have significantly advanced treatment, a substantial fraction of patients still do not achieve sustained clinical remission or mucosal healing. Mucosal healing, defined by endoscopic remission, is increasingly recognized as a crucial therapeutic goal, correlating with improved long-term outcomes and reduced disease complications. The Phase 2a TARGET-CD study's finding that ABBV-466 achieved higher endoscopic remission rates than either monotherapy is therefore highly significant, suggesting that a combined approach within a single molecule could offer a more potent and comprehensive therapeutic effect.

This dual-targeting strategy could provide a strong competitive advantage, potentially establishing ABBV-466 as a new standard of care, particularly for patients who have failed or are inadequately controlled by current monotherapies. However, the journey from Phase 2a to clinical practice is fraught with challenges. The promising efficacy and safety observed in this early-phase trial must be rigorously validated in larger, longer Phase 3 studies. Furthermore, while dual targeting offers enhanced efficacy, the safety profile of combining two mechanisms will require careful scrutiny. The inflammatory bowel disease landscape is also rapidly evolving, with numerous novel agents and combination strategies under investigation. ABBV-466 will need to demonstrate sustained, superior long-term benefits and a favorable safety profile to carve out a dominant position. If successful, this innovative approach could offer a more effective, single-agent solution, potentially simplifying treatment regimens and improving the lives of patients living with Crohn's disease.